GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

In marriage and in partnership, you’re supposed to share things. Among them: taxes, household chores, gossip, cars, and your ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at ...

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3; No significant safety or dose ...

Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, ...

Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. It may become ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

With GLP-1 weight loss comes muscle loss. Gyms and personal trainers are rising to the challenge to help people build it back ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...